Benefits
Reduced hot flashes and night sweats
In a 70-person double-blind, placebo-controlled trial in peri- and postmenopausal women (Gudise 2024), the shatavari group had significantly fewer hot flashes and night sweats than the placebo group. A separate 8-week trial in 80 perimenopausal women (73 completed) using 300 mg of shatavari root extract once daily also reported improvement in hot flashes versus placebo (p=0.002). Both trials are small, and the published report of the 70-person trial does not name a branded extract.
Improved sleep and reduced insomnia
In the 70-person Gudise 2024 trial, women taking shatavari reported less insomnia than those taking placebo. This rests on one small trial, so treat it as early rather than settled evidence.
Anxiety, nervousness, and mood symptom relief
In the 70-person Gudise 2024 trial, anxiety and nervousness improved more than with placebo. In a separate 8-week trial in 135 women aged 45 to 65, mood improved (p=0.008) and esteem-related affect improved (p=0.025) between groups. That trial had both a shatavari-alone arm and an ashwagandha-plus-shatavari arm, so any result from the combination arm cannot be credited to shatavari on its own.
Vaginal dryness and libido improvement
The 70-person Gudise 2024 trial reported greater improvement in vaginal dryness and libido than placebo. This comes from that single small trial. How it works is not established; researchers have proposed mild plant-estrogen activity combined with effects on the stress response.
Quality of life improvement
Utian Quality of Life scores improved significantly versus placebo in the 70-person Gudise 2024 trial. In the 135-woman trial, MENQOL (Menopause-Specific Quality of Life Questionnaire) scores improved numerically by week 8, meaning the change went in the expected direction but was not reported as statistically significant.
Mechanism of action
Phytoestrogenic activity of Shatavarins
Shatavarin saponins have a steroidal structure resembling endogenous estrogens and bind weakly to estrogen receptors. This weak, SERM-like binding is the leading explanation for symptom relief, but it is a proposal rather than something the human trials tested. It should not be read as proof of safety: one of the cited trials measured changes in estradiol, FSH and T3, so anyone with a hormone-sensitive condition should speak to a doctor first.
Adaptogenic HPA-axis modulation
Shatavari is classified as a rasayana in Ayurveda — a category overlapping with the modern adaptogen concept. Animal studies show effects on the hypothalamic-pituitary-adrenal stress axis and a reduced cortisol response to stress. Whether this explains the anxiety and sleep changes seen in people has not been tested, because the human trials did not measure it.
GABAergic and 5-HT receptor effects
Preclinical work has identified GABAergic activity and serotonergic receptor modulation by Shatavari extracts — mechanisms that could contribute to anxiolytic and sleep-promoting effects. This is all laboratory and animal research, and no human trial of shatavari has measured these pathways, so it remains a hypothesis.
Antioxidant and anti-inflammatory activity
Asparagus racemosus root contains saponins, isoflavones, and polysaccharides with documented antioxidant activity. That activity has been measured in the laboratory, not in people. None of the human trials cited here measured oxidative stress or any healthy-aging outcome, so this is background chemistry rather than a demonstrated benefit.
Clinical trials
Double-blind, multicenter, randomized, placebo-controlled clinical trial (Gudise VS, Dasari MP, Kuricheti SSK 2024, Cureus 16(4):e57879, doi:10.7759/cureus.57879). Important limitation: the published report does not name a branded extract. It refers only to the test group and the test compound, and identifies the plant only as Asparagus racemosus. No trademark, no standardization percentage and no dose appear in it. The listed affiliations are two Indian hospitals and an Ayurveda practice, with no company named and no funding statement, so who funded the trial is not stated.
70 peri- and postmenopausal women with menopausal symptoms (hot flashes, night sweats, anxiety, fatigue, depression, insomnia, mood swings), randomized to two groups of 35: shatavari root extract or a microcrystalline cellulose placebo. Thirty-five people per group is a small trial.
The shatavari group improved more than placebo in hot flashes, night sweats, insomnia, anxiety, nervousness, vaginal dryness and loss of libido, and Utian Quality of Life scores improved significantly. No significant adverse events were recorded. The authors' own wording was that the test compound could be a safe alternative to modern drugs. No trial cited here compared shatavari with hormone replacement therapy, so nothing in this research shows it can stand in for HRT; that decision belongs with your doctor.
8-week, randomized, double-blind, placebo-controlled, multicentric study (Ademola, Ajgaonkar, Debnath, Debnath, Frontiers in Reproductive Health, doi:10.3389/frph.2025.1654503).
135 women aged 45 to 65 with menopausal symptoms, randomized to three groups for 8 weeks: shatavari root extract alone, an ashwagandha plus shatavari combination, or placebo. The published report does not state the dose used; among the trials cited here, only the perimenopause study states a dose (300 mg once daily).
MRS (Menopause Rating Scale) scores improved at weeks 4 and 8. Esteem-related affect improved (p=0.025) and mood improved significantly (p=0.008) between groups. MENQOL scores improved numerically by week 8. This trial reported that hormone levels stayed within normal limits. That is not the whole picture: a third cited trial in perimenopausal women (Mahajan 2025) reported measurable changes in estradiol (p=0.003), FSH (p=0.028) and T3 (p=0.021), so shatavari should not be described as having no hormonal effect. Mild adverse events reported in 4 participants (loose stools, dizziness, nausea, headache). The authors concluded that the ashwagandha plus shatavari combination is a promising option for managing menopausal symptoms; that conclusion is about the combination, not about shatavari on its own.